Abiraterone

Lynparza ( Olaparib ) has been approved in the European Union ( EU ) for patients with metastatic castration-resistant prostate...


Cabozantinib ( Cabometyx ) may enhance response to immune checkpoint inhibitors ( ICIs ) by promoting an immune-permissive microenvironment and...


SPARTAN has evaluated Apalutamide ( Erleada ) versus placebo in patients with nonmetastatic castration-resistant prostate cancer ( nmCRPC ) and...


Tthe phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival ( rPFS ) in patients with metastatic...


Data, presented at 2018 American Society of Clinical Oncology ( ASCO ) Annual Meeting, showed clinical improvement in median radiologic...


ADXS-PSA, an attenuated Listeria monocytogenes-based immunotherapy that targets prostate-specific antigen ( PSA ), is designed to generate antigen-specific T cell...


Researchers have evaluated the use of Abiraterone acetate ( Zytiga ) ( 1,000 mg ) plus Prednisone ( 5 mg...


Data from the pivotal phase 3 LATITUDE clinical trial showed Abiraterone acetate ( Zytiga ) plus Prednisone, in combination with...


STAMPEDE is a multigroup, multistage platform trial protocol investigating the efficacy of additional therapy at the time of inception of...


Over the past decade, several systemic agents as Docetaxel, Cabazitaxel, Sipuleucel-T, Abiraterone and Enzalutamide have improved overall survival ( OS...


Researchers aimed to identify clinical predictors of long-term response to Abiraterone [ Zytiga ] ( defined as more than 12...


The aim of a study was to evaluate the safety profile of Abiraterone acetate ( Zytiga ) in metastatic castration-resistant...


The ASCO Task Force has applied the Framework to four clinical scenarios in which multiple trials have compared new treatment...


In a phase III clinical trial, the hormone therapy Enzalutamide ( Xtandi ) extended survival in men with metastatic prostate...


Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. Researchers have...